Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | SLC10A1 | Q14973 | 4/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 6/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.34 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.34 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.34 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15613075 | 0.94 | GRM4 (0.40) | GRM4SLC10A1LRRK2BACE1 | |
| SCHEMBL15612929 | 0.93 | GRM4 (0.40) | GRM4SLC10A1LRRK2BACE1AKT1 | |
| SCHEMBL15613006 | 0.93 | GRM4 (0.42) | GRM4SLC10A1LRRK2BACE1 | |
| SCHEMBL16236953 | 0.84 | SLC10A1 (0.41) | GRM4SLC10A1BACE1AKT1KIF18A | |
| SCHEMBL15612928 | 0.82 | HTR2B (0.41) | KIF18ACA1CA2CA9 | |
| SCHEMBL15613089 | 0.82 | IDH1 (0.42) | — | |
| SCHEMBL16257247 | 0.81 | SLC10A1 (0.43) | GRM4SLC10A1LRRK2BACE1AKT1 | |
| SCHEMBL16237229 | 0.81 | GRM4 (0.41) | GRM4SLC10A1BACE1AKT1EGLN2 | |
| SCHEMBL15612992 | 0.79 | HTR2B (0.40) | BACE1KIF18ACA1CA2CA9 | |
| SCHEMBL15613095 | 0.79 | IDH1 (0.46) | SLC10A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024462-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024462-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | GRM4 3624/4885SLC10A1 11/4885LRRK2 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.